{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:02:16Z","timestamp":1790373736783,"version":"4.1.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":275,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016618","name":"Gilbert Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016618","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1R35NS142919-01"],"award-info":[{"award-number":["1R35NS142919-01"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Authenticated preclinical brain tumor models provide unprecedented opportunities to evaluate next-generation treatments. However, some therapies with robust anti-tumor activity in mice fail in human trials, highlighting the need to better prioritize candidates for clinical translation. Herein, we implemented a head-to-head preclinical strategy using a well-characterized murine model of NF1-optic pathway glioma (Nf1OPG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Nf1 OPG mice were treated with standard of care (SOC; carboplatin), clinically evaluated (everolimus, mirdametinib), and investigational (pexidartinib, HBS-101, lamotrigine) drugs during the period of most rapid tumor growth (6-12 weeks of age). Anti-tumoral efficacy was assessed by proliferation (%Ki67+ cells) and optic nerve (ON) volume, while vision-related outcomes were measured using retinal nerve fiber layer (RNFL) thickness and retinal ganglion cell (RGC) determinations. Tumor microenvironment (TME) soluble mediator (Ccl2, Ccl3, Ccl4, Ccl5) and tumor cell marker (NeuN, Gpr17) RNA expression was quantitated by qRT-PCR. Outcomes were compared to carboplatin-treated Nf1OPG, untreated Nf1OPG, and Nf1+\/- mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>While all agents restored normal tissue architecture, reduced ON proliferation, and decreased TME soluble mediator and tumor cell marker RNA expression, only lamotrigine and mirdametinib also reduced ON volume. Everolimus, lamotrigine, and HBS-101 restored RNFL thickness to wild-type levels, whereas carboplatin showed a trend towards normalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This referential preclinical study design affords direct head-to-head comparisons of investigational therapies relative to SOC treatment using clinically meaningful outcomes (OPG growth and RNFL thickness). Using this strategy, lamotrigine emerged as the most promising therapy for limiting tumor progression and vision loss in Nf1-OPG mice, relevant to clinical translation for children with NF1-OPG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdaf215","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:12:38Z","timestamp":1759320758000},"source":"Crossref","is-referenced-by-count":3,"title":["Head-to-head preclinical treatment design prioritizes promising therapies for neurofibromatosis type 1 optic glioma clinical translation"],"prefix":"10.1093","volume":"7","author":[{"given":"Talia","family":"Eligator","sequence":"first","affiliation":[{"name":"Washington University School of Medicine, Department of Neurology, Saint Louis, MO (T.E., J.C., S.Y., A.K., D.H.G.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2444-9748","authenticated-orcid":false,"given":"Jit","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Department of Neurology, Saint Louis, MO (T.E., J.C., S.Y., A.K., D.H.G.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Yamada","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Department of Neurology, Saint Louis, MO (T.E., J.C., S.Y., A.K., D.H.G.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Kirchner","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Department of Neurology, Saint Louis, MO (T.E., J.C., S.Y., A.K., D.H.G.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hareesh B","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Molecular and Translational Medicine, Texas Tech University Health Science Center, \u00a0 Rick Francis St, El Paso, Texas, 79905 (H.B.N.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R","family":"Fangusaro","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children\u2019s Healthcare of Atlanta and the Aflac Cancer Center, Emory University School of Medicine , Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3127-5045","authenticated-orcid":false,"given":"David H","family":"Gutmann","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Department of Neurology, Saint Louis, MO (T.E., J.C., S.Y., A.K., D.H.G.)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,4]]},"reference":[{"key":"2026010519025572200_vdaf215-B1","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/jnci\/djae249","article-title":"Precision preclinical modeling to advance cancer treatment","volume":"117","author":"Gutmann","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"2026010519025572200_vdaf215-B2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/CCO.0000000000000997","article-title":"Preclinical glioma models in neuro-oncology: enhancing translational research","volume":"35","author":"Barachini","year":"2023","journal-title":"Curr Opin Oncol"},{"key":"2026010519025572200_vdaf215-B3","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/neuonc\/noad125","article-title":"Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation","volume":"25","author":"Milde","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026010519025572200_vdaf215-B4","first-page":"8573","article-title":"Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity","volume":"63","author":"Bajenaru","year":"2003","journal-title":"Cancer Res"},{"key":"2026010519025572200_vdaf215-B5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/neuonc\/nou329","article-title":"Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth","volume":"17","author":"Kaul","year":"2015","journal-title":"Neuro Oncol"},{"key":"2026010519025572200_vdaf215-B6","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/neuonc\/nos076","article-title":"Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis","volume":"14","author":"Fisher","year":"2012","journal-title":"Neuro Oncol"},{"key":"2026010519025572200_vdaf215-B7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-3476(94)70122-9","article-title":"Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study","volume":"125","author":"Listernick","year":"1994","journal-title":"J Pediatr"},{"key":"2026010519025572200_vdaf215-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-012-0944-y","article-title":"Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research","volume":"110","author":"Avery","year":"2012","journal-title":"J Neurooncol"},{"key":"2026010519025572200_vdaf215-B9","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ajo.2010.08.046","article-title":"Retinal nerve fiber layer thickness in children with optic pathway gliomas","volume":"151","author":"Avery","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"2026010519025572200_vdaf215-B10","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/WNO.0000000000000550","article-title":"Optic pathway gliomas in neurofibromatosis type 1: an update: surveillance, treatment indications, and biomarkers of vision","volume":"37","author":"de Blank","year":"2017","journal-title":"J Neuroophthalmol"},{"key":"2026010519025572200_vdaf215-B11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/neuonc\/noad195","article-title":"Pediatric low-grade glioma: state-of-the-art and ongoing challenges","volume":"26","author":"Fangusaro","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026010519025572200_vdaf215-B12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/neuonc\/2.4.213","article-title":"Carboplatin is effective therapy for young children with progressive optic pathway tumors: a pediatric oncology group phase II study","volume":"2","author":"Mahoney","year":"2000","journal-title":"Neuro Oncol"},{"key":"2026010519025572200_vdaf215-B13","doi-asserted-by":"crossref","first-page":"e27351","DOI":"10.1002\/pbc.27351","article-title":"Carboplatin and vincristine neurotoxicity in the treatment of pediatric low-grade gliomas","volume":"65","author":"Rosca","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"2026010519025572200_vdaf215-B14","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.2016.68.1585","article-title":"Phase II weekly vinblastine for chemotherapy-naive children with progressive low-grade glioma: a Canadian pediatric brain tumor consortium study","volume":"34","author":"Lassaletta","year":"2016","journal-title":"J Clin Oncol"},{"issue":":","key":"2026010519025572200_vdaf215-B15","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1093\/neuonc\/noaf065","article-title":"A phase 2 PBTC study of selumetinib for recurrent\/progressive pediatric low-grade glioma: Strata 2, 5, and 6 WITH long-term outcomes on strata 1, 3, and 4","volume":"27","author":"Fangusaro","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026010519025572200_vdaf215-B16","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/neuonc\/noaa071","article-title":"A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a neurofibromatosis clinical trials consortium study","volume":"22","author":"Ullrich","year":"2020","journal-title":"Neuro Oncol"},{"key":"2026010519025572200_vdaf215-B17","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat Med"},{"key":"2026010519025572200_vdaf215-B18","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/neuonc\/noae054","article-title":"NF1 mutation-driven neuronal hyperexcitability sets a threshold for tumorigenesis and therapeutic targeting of murine optic glioma","volume":"26","author":"Anastasaki","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026010519025572200_vdaf215-B19","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1038\/s41467-022-30466-6","article-title":"Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1","volume":"13","author":"Anastasaki","year":"2022","journal-title":"Nat Commun"},{"key":"2026010519025572200_vdaf215-B20","first-page":"vdab194","article-title":"Immune deconvolution and temporal mapping identifies stromal targets and developmental intervals for abrogating murine low-grade optic glioma formation","volume":"4","author":"de Andrade Costa","year":"2022","journal-title":"Neurooncol Adv"},{"key":"2026010519025572200_vdaf215-B21","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1158\/0008-5472.CAN-04-4058","article-title":"Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors","volume":"65","author":"Dasgupta","year":"2005","journal-title":"Cancer Res"},{"key":"2026010519025572200_vdaf215-B22","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/s41467-020-15770-3","article-title":"Midkine activation of CD8(+) T cells establishes a neuron-immune-cancer axis responsible for low-grade glioma growth","volume":"11","author":"Guo","year":"2020","journal-title":"Nat Commun"},{"key":"2026010519025572200_vdaf215-B23","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1158\/1535-7163.MCT-25-0130","article-title":"The discovery and characterization of HBS-101, a novel inhibitor of midkine, as a therapeutic agent for the treatment of triple negative breast cancer","volume":"24","author":"Mahajan","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"2026010519025572200_vdaf215-B24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1084\/jem.20120412","article-title":"Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival","volume":"210","author":"Luo","year":"2013","journal-title":"J Exp Med"},{"key":"2026010519025572200_vdaf215-B25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2174\/156802609789007327","article-title":"Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease","volume":"9","author":"Patel","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"2026010519025572200_vdaf215-B26","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/neuonc\/noaf024","article-title":"Intestinal bacteroides drives glioma progression by regulating CD8+ T cell tumor infiltration","volume":"27","author":"Chatterjee","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026010519025572200_vdaf215-B27","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/neuonc\/noz080","article-title":"Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell-specific chemokine recruitment of T cells and microglia","volume":"21","author":"Guo","year":"2019","journal-title":"Neuro Oncol"},{"key":"2026010519025572200_vdaf215-B28","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1212\/01.wnl.0000435745.95155.b8","article-title":"Functional outcome measures for NF1-associated optic pathway glioma clinical trials","volume":"81","author":"Fisher","year":"2013","journal-title":"Neurology"},{"key":"2026010519025572200_vdaf215-B29","first-page":"808","article-title":"Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction","volume":"19","author":"Toonen","year":"2017","journal-title":"Neuro Oncol"},{"key":"2026010519025572200_vdaf215-B30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ana.24093","article-title":"Sex is a major determinant of neuronal dysfunction in neurofibromatosis type 1","volume":"75","author":"Diggs-Andrews","year":"2014","journal-title":"Ann Neurol"},{"key":"2026010519025572200_vdaf215-B31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1084\/jem.20160447","article-title":"Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic glioma-induced retinal pathology","volume":"214","author":"Toonen","year":"2017","journal-title":"J Exp Med"},{"key":"2026010519025572200_vdaf215-B32","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/NEN.0b013e318165eb75","article-title":"Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients","volume":"67","author":"Rodriguez","year":"2008","journal-title":"J Neuropathol Exp Neurol"},{"key":"2026010519025572200_vdaf215-B33","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/cncr.29987","article-title":"Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: a report from the children\u2019s oncology group","volume":"122","author":"Ater","year":"2016","journal-title":"Cancer"},{"key":"2026010519025572200_vdaf215-B34","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1158\/1078-0432.CCR-23-3386","article-title":"Considering functional outcomes as efficacy endpoints in pediatric low-grade glioma clinical trials: an FDA educational symposium","volume":"30","author":"Fangusaro","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026010519025572200_vdaf215-B35","doi-asserted-by":"crossref","first-page":"e28833","DOI":"10.1002\/pbc.28833","article-title":"Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children","volume":"68","author":"Ullrich","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"2026010519025572200_vdaf215-B36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41586-021-03580-6","article-title":"NF1 mutation drives neuronal activity-dependent initiation of optic glioma","volume":"594","author":"Pan","year":"2021","journal-title":"Nature"},{"key":"2026010519025572200_vdaf215-B37","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nature24014","article-title":"Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma","volume":"549","author":"Venkatesh","year":"2017","journal-title":"Nature"},{"key":"2026010519025572200_vdaf215-B38","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/acn3.51995","article-title":"Estrogen-induced glial IL-1beta mediates extrinsic retinal ganglion cell vulnerability in murine Nf1 optic glioma","volume":"11","author":"Tang","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"2026010519025572200_vdaf215-B39","doi-asserted-by":"crossref","first-page":"7122","DOI":"10.1038\/s41467-021-27455-6","article-title":"Asthma reduces glioma formation by T cell decorin-mediated inhibition of microglia","volume":"12","author":"Chatterjee","year":"2021","journal-title":"Nat Commun"},{"key":"2026010519025572200_vdaf215-B40","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1093\/hmg\/ddq382","article-title":"Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice","volume":"19","author":"Brown","year":"2010","journal-title":"Hum Mol Genet"},{"key":"2026010519025572200_vdaf215-B41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41568-024-00756-w","article-title":"Challenging the status quo to improve the translational potential of preclinical oncology studies","volume":"25","author":"Connor","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"2026010519025572200_vdaf215-B42","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s00247-013-2694-1","article-title":"Optic nerve tortuosity in children with neurofibromatosis type 1","volume":"43","author":"Ji","year":"2013","journal-title":"Pediatr Radiol"},{"key":"2026010519025572200_vdaf215-B43","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/hmg\/ddm059","article-title":"Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth","volume":"16","author":"Daginakatte","year":"2007","journal-title":"Hum Mol Genet"},{"key":"2026010519025572200_vdaf215-B44","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ajo.2015.07.036","article-title":"Longitudinal change of circumpapillary retinal nerve fiber layer thickness in children with optic pathway gliomas","volume":"160","author":"Avery","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"2026010519025572200_vdaf215-B45","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026010519025572200_vdaf215-B46","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/neuonc\/now282","article-title":"A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a pediatric brain tumor consortium (PBTC) study","volume":"19","author":"Banerjee","year":"2017","journal-title":"Neuro Oncol"},{"key":"2026010519025572200_vdaf215-B47","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0022-3476(95)70047-1","article-title":"Lamotrigine for the treatment of epilepsy in childhood","volume":"127","author":"Besag","year":"1995","journal-title":"J Pediatr"},{"key":"2026010519025572200_vdaf215-B48","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.cell.2023.02.002","article-title":"Cancer neuroscience: state of the field, emerging directions","volume":"186","author":"Winkler","year":"2023","journal-title":"Cell"},{"key":"2026010519025572200_vdaf215-B49","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1016\/j.cell.2025.05.031","article-title":"Cholinergic neuronal activity promotes diffuse midline glioma growth through muscarinic signaling","volume":"188","author":"Drexler","year":"2025","journal-title":"Cell"},{"key":"2026010519025572200_vdaf215-B50","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cell.2015.04.012","article-title":"Neuronal activity promotes glioma growth through neuroligin-3 secretion","volume":"161","author":"Venkatesh","year":"2015","journal-title":"Cell"},{"key":"2026010519025572200_vdaf215-B51","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/s41586-024-08579-3","article-title":"GABAergic neuron-to-glioma synapses in diffuse midline gliomas","volume":"639","author":"Barron","year":"2025","journal-title":"Nature"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdaf215\/64488782\/vdaf215.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf215\/64488782\/vdaf215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf215\/64488782\/vdaf215.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:03:28Z","timestamp":1767657808000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaf215\/8272888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaf215","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]},"article-number":"vdaf215"}}